Posoleucel (Viralym-M, ALVR105): A multi-virus specific T cell therapy (VST) targeting six devastating viruses
Life-threatening viral infections and diseases post transplantation
The immune systems of individuals undergoing potentially life-saving transplantations – the two most common types of which are allogeneic hematopoietic cell transplant (HCT) and solid organ transplant (SOT) – are suppressed or eliminated to prevent rejection of the transplanted cells or organs, leaving the patient highly prone to devastating viral infections or diseases, which can cause end-organ damage and mortality.
Allogeneic HCT conditioning regimens often require the complete elimination of a patient’s own stem cells, leaving patients without a functioning immune system and in a severely immunocompromised state post HCT. For 90% of allogeneic HCT patients, their suppressed immune system allows viruses that were previously in a latent state to reactivate, with more than 60% of HCT patients experiencing reactivation of more than one potentially fatal virus.
Currently, there are limited therapies for most viral infections in the post-transplant setting. The standard of care treatments have limited efficacy and are associated with significant toxicity.
Restoring Immunity with Posoleucel (Viralym-M, ALVR105)
Posoleucel is designed to restore T cell immunity in patients during the time of severe immune compromise between conditioning and reconstitution of patients’ immune systems.